Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

November 14, 2005 09:02 ET

Swiss Medica Continues Aggressive Marketing and Sampling Programs for O24 Pain Neutralizer

TORONTO, ONTARIO--(CCNMatthews - Nov. 14, 2005) - Swiss Medica, Inc. (OTCBB:SWME) today announced that it has launched marketing programs with nationally syndicated radio programs to offer free samples of Swiss Medica's flagship brand O24 Pain Neutralizer to their national U.S. audiences.

Swiss Medica has recently launched a series of personally endorsed radio commercials with Dr. Laura Schlessinger ("Dr. Laura"). The syndicated Dr. Laura radio show is broadcast daily on 200 affiliate radio stations across the U.S. representing an 82% market penetration. Dr. Laura is the number one daily talk show in North America targeted at adult women and has an estimated weekly listening audience of 7.75 million. Dr. Laura is a user of O24 Pain Neutralizer and will talk about O24 daily during the course of her radio show.

Swiss Medica has also launched an extensive campaign for O24 Pain Neutralizer on U.S. nationally syndicated Fox Radio Sports. This campaign features personal endorsements by Fox personalities David Stein (morning show host), JT the Brick (late afternoon host) and Craig Shemon and James Washington (Game Time Live hosts). In each case, these personalities are using O24 Pain Neutralizer and benefiting from this safe and effective pain reliever. For examples of the Fox Radio Sports spots, please visit www.024zone.com/foxclips

In Canada, Swiss Medica has continued innovative media and sampling programs including the recently launched National Hockey League ("NHL") O24Zone Injury Report which appears on radio broadcasts for all 6 Canadian NHL professional hockey teams. This exclusive program also includes O24 Pain Neutralizer sampling to all guests on the radio broadcasts.

These media programs are an extension of the aggressive sampling and media program that Swiss Medica has been executing since the pharmacy launch of O24 Pain Neutralizer in fall of 2004. By the end of 2005, Swiss Medica will have distributed over 500,000 samples of O24 Pain Neutralizer to North American adults in medical and doctors offices, in pharmacies and other retailers, via media opportunities and at trade and consumer shows.

O24 Pain Neutralizer is available in the pain relief section of more that 19,000 North American retail outlets including the top 3 national drug chains in the USA. Please visit www.O24zone.com, for store locators.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact: David Jones
    (866) 485-4243
    or
    Fusion Communications
    Media Contact: Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca